
Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
Subhasis Banerjee, PhD, is principal technical application expert, Bioprocessing APAC, at Merck Life Sciences Pvt, Ltd.

Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Published: March 16th 2024 | Updated: